Prediction of warfarin maintenance dose in Han Chinese Patients using a mechanistic model based on genetic and non-genetic factors

Clinical Pharmacokinetics

Volumn 52, Issue 7, 2013, Pages 567-581

  Yang, Jin ^a   Lu, Yuan ^a   Yang, Jinbo ^b   Zhang, Haiyan ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b CENTER FOR DRUG EVALUATION   (China)

^c Wujin Hospital Affiliated with Jiangsu University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CHINESE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; GENETIC MODEL; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; IN VITRO STUDY; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STEADY STATE;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; VITAMIN K EPOXIDE REDUCTASES; WARFARIN; YOUNG ADULT;

EID: 84879646843     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0054-9     Document Type: Article

References (53)

1. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics. 2003;13(5):247-52.
2. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326-31.
3. Lane S, Al-Zubiedi S, Hatch E, et al. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol. 2012;73(1):66-76.
4. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358(10):999-1008.
5. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007;7(2):99-111.
6. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008;112(4):1022-7.
7. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003;3(3):221-30.
8. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74.
9. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40(8):587-603.
10. Cain D, Hutson SM, Wallin R. Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J Biol Chem. 1997;272(46):29068-75.
11. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329-33.
12. Yuan HY. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14(13):1745-51.
13. Suriapranata IM, Tjong WY, Wang T, et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med Genet. 2011;12:80.
14. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005;106(1):135-40.
15. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5(4):262-70.
16. Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res. 2007;120(2):181-6.
17. Linder MW, Bon Homme M, Reynolds KK, et al. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. Clin Chem. 2009;55(10):1861-8.
18. Miao L, Yang J, Huang C, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol. 2007;63(12):1135-41.
19. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet. 2009;24(1):53-75.
20. Dickinson GL, Lennard MS, Tucker GT, et al. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies - CYP2C9 and warfarin as an example. Br J Clin Pharmacol. 2007;64(1):14-26.
21. Chan E, McLachlan A, O'Reilly R, et al. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther. 1994;56(3):286-94.
22. Yuen E, Gueorguieva I, Wise S, et al. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn. 2010;37(1):3-24.
23. Hamberg AK, Dahl ML, Barban M, et al. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther. 2007;81(4):529-38.
24. Gong IY, Schwarz UI, Crown N, et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One. 2011;6(11):e27808.
25. Hamberg AK, Wadelius M, Lindh JD, et al. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther. 2010;87(6):727-34.
26. Wright DF, Duffull SB. Development of a bayesian forecasting method for warfarin dose individualization. Pharm Res. 2011;28(5):1100-11.
27. Pitsiu M, Parker EM, Aarons L, et al. Population pharmacokinetics and pharmacodynamics of warfarin in healthy-young adults. Eur J Pharm Sci. 1993;1(3):151-7.
28. Wajima T, Isbister GK, Duffull SB. A comprehensive model for the humoral coagulation network in humans. Clin Pharmacol Ther. 2009;86(3):290-8.
29. Zhang H, Xue L, Qi C, et al. Effect of gene and clinical factors on the dose of warfarin [in Chinese]. China Pharmacy. 2010;21(22):2049-52.
30. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov. 2007;6(2):140-8.
31. Barter ZE, Bayliss MK, Beaune PH, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab. 2007;8(1):33-45.
32. Austin RP, Barton P, Cockroft SL, et al. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos. 2002;30(12):1497-503.
33. Yu CY, Lo YH, Chiou WK. The 3D scanner for measuring body surface area: a simplified calculation in the Chinese adult. Appl Ergon. 2003;34(3):273-8.
34. Johnson TN, Tucker GT, Tanner MS, et al. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 2005;11(12):1481-93.
35. Heinemann A, Wischhusen F, Puschel K, et al. Standard liver volume in the Caucasian population. Liver Transpl Surg. 1999;5(5):366-8.
36. Henderson JM, Gilmore GT, Mackay GJ, et al. Hemodynamics during liver transplantation: the interactions between cardiac output and portal venous and hepatic arterial flows. Hepatology. 1992;16(3):715-8.
37. Katori R. Normal cardiac output in relation to age and body size. Tohoku J Exp Med. 1979;128(4):377-87.
38. Takahashi H, Kashima T, Nomoto S, et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics. 1998;8(5):365-73.
39. Wang SL, Huang J, Lai MD, et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 1995;5(1):37-42.
40. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics. 1997;7(5):405-9.
41. Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica. 2004;34(2):151-78.
42. Crewe HK, Barter ZE, Yeo KR, et al. Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. Biopharm Drug Dispos. 2011;32(6):303-18.
43. Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev. 1997;29(4):891-922.
44. Obach RS. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos. 1997;25(12):1359-69.
45. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377-90.
46. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27(11):1350-9.
47. Choppin A, Irwin I, Lach L, et al. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs. Br J Pharmacol. 2009;158(6):1536-47.
48. Wang D, Chen H, Momary KM, et al. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood. 2008;112(4):1013-21.
49. Chan SC, Liu CL, Lo CM, et al. Estimating liver weight of adults by body weight and gender. World J Gastroenterol. 2006;12(14):2217-22.
50. McDonald MG, Rieder MJ, Nakano M, et al. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol. 2009;75(6):1337-46.
51. Scott AK, Haynes BP, Schinkel KD, et al. Hepatic enzyme induction and vitamin K1 elimination in man. Eur J Clin Pharmacol. 1987;33(1):93-5.
52. Avery PJ, Jorgensen A, Hamberg AK, et al. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther. 2011;90(5):701-6.
53. Frymoyer A, Shugarts S, Browne M, et al. Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther. 2010;88(4):540-7.